Education
About Us
Working with TipRanks
Follow Us
Fulcrum Therapeutics (FULC)
NASDAQ:FULC
FULC Analyst Ratings
Moderate Buy
5 Buy
1 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
FULC Stock 12 Month Forecast
Average Price Target
$9.86
▲(44.36%Upside)
| Highest Price Target$15.00 | Average Price Target$9.86 | Lowest Price Target$5.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$7.5
Hold
9.81%
Upside
Reiterated
07/31/25
Fulcrum Therapeutics' overall stock score of 60.15 reflects a blend of strengths and challenges. The company's strong financial foundation and promising trial developments are counterbalanced by ongoing profitability issues and valuation concerns. The positive sentiment from recent earnings calls and corporate events supports future growth potential, but operational improvements are critical.
Leerink Partners
$12
Buy
75.70%
Upside
Reiterated
07/30/25
RBC Capital
$4→$5
Hold
-26.79%
Downside
Reiterated
07/30/25
H.C. Wainwright
$4→$12
Buy
75.70%
Upside
Upgraded
07/29/25
Buy Rating for Fulcrum Therapeutics: Promising Potential of Pociredir in Sickle Cell Disease TreatmentValuation and Risks. Given the positive SCD data, we have increased our to 35%. Hence we are upgrading our rating to Buy from Neutral. Our new 12-month price target of $12, up from $4, is based on an equally weighted composite of (a) $14.32/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of $1.98 discounted back to and (b) an NPV of $9.31/ share (discount rate 12.0%, growth rate 2.0%). The assumptions are in line with the expected P/E multiple and discount rate of an early development-stage biopharmaceutical company.
Oppenheimer
$12→$15
Buy
119.62%
Upside
Reiterated
07/29/25
Bank of America Securities
$2→$6
Sell
-12.15%
Downside
Reiterated
07/01/25
Cantor Fitzgerald
$10
Buy
46.41%
Upside
Reiterated
06/20/25
Piper Sandler
$9
Buy
31.77%
Upside
Reiterated
06/16/25
Stifel Nicolaus
$22→$3
Hold
-56.08%
Downside
Reiterated
09/26/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$7.5
Hold
9.81%
Upside
Reiterated
07/31/25
Fulcrum Therapeutics' overall stock score of 60.15 reflects a blend of strengths and challenges. The company's strong financial foundation and promising trial developments are counterbalanced by ongoing profitability issues and valuation concerns. The positive sentiment from recent earnings calls and corporate events supports future growth potential, but operational improvements are critical.
Leerink Partners
$12
Buy
75.70%
Upside
Reiterated
07/30/25
RBC Capital
$4→$5
Hold
-26.79%
Downside
Reiterated
07/30/25
H.C. Wainwright
$4→$12
Buy
75.70%
Upside
Upgraded
07/29/25
Buy Rating for Fulcrum Therapeutics: Promising Potential of Pociredir in Sickle Cell Disease TreatmentValuation and Risks. Given the positive SCD data, we have increased our to 35%. Hence we are upgrading our rating to Buy from Neutral. Our new 12-month price target of $12, up from $4, is based on an equally weighted composite of (a) $14.32/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of $1.98 discounted back to and (b) an NPV of $9.31/ share (discount rate 12.0%, growth rate 2.0%). The assumptions are in line with the expected P/E multiple and discount rate of an early development-stage biopharmaceutical company.
Oppenheimer
$12→$15
Buy
119.62%
Upside
Reiterated
07/29/25
Bank of America Securities
$2→$6
Sell
-12.15%
Downside
Reiterated
07/01/25
Cantor Fitzgerald
$10
Buy
46.41%
Upside
Reiterated
06/20/25
Piper Sandler
$9
Buy
31.77%
Upside
Reiterated
06/16/25
Stifel Nicolaus
$22→$3
Hold
-56.08%
Downside
Reiterated
09/26/24
Best Analysts Covering Fulcrum Therapeutics
1 Month
xxx
Success Rate
8/10 ratings generated profit
Average Return
+7.58%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +7.58% per trade.
3 Months
xxx
Success Rate
6/10 ratings generated profit
Average Return
-5.56%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of -5.56% per trade.
1 Year
Success Rate
8/15 ratings generated profit
Average Return
+32.39%
reiterated a buy rating 5 days ago
Copying Matthew Biegler's trades and holding each position for 1 Year would result in 53.33% of your transactions generating a profit, with an average return of +32.39% per trade.
2 Years
xxx
Success Rate
7/15 ratings generated profit
Average Return
+16.65%
reiterated a xxx
rating 5 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 46.67% of your transactions generating a profit, with an average return of +16.65% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
FULC Analyst Recommendation Trends
Rating
Nov 24
Feb 25
May 25
Jun 25
Jul 25
Strong Buy
2
3
7
6
7
Buy
0
0
2
4
4
Hold
11
7
10
7
11
Sell
1
1
1
1
1
Strong Sell
0
0
1
1
1
total
14
11
21
19
24
Each month's total comprises the sum of three months' worth of ratings.
FULC Financial Forecast
FULC Stock Forecast FAQ
What is FULC’s average 12-month price target, according to analysts?
Based on analyst ratings, Fulcrum Therapeutics’s 12-month average price target is 9.86.
What is FULC’s upside potential, based on the analysts’ average price target?
Fulcrum Therapeutics has 44.36% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is FULC a Buy, Sell or Hold?
Fulcrum Therapeutics has a consensus rating of Moderate Buy which is based on 5 buy ratings, 1 hold ratings and 1 sell ratings.
What is Fulcrum Therapeutics’s price target?
The average price target for Fulcrum Therapeutics is 9.86. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $15.00 ,the lowest forecast is $5.00. The average price target represents 44.36% Increase from the current price of $6.83.
The highest analyst price target is $15.00 ,the lowest forecast is $5.00. The average price target represents 44.36% Increase from the current price of $6.83.
What do analysts say about Fulcrum Therapeutics?
Fulcrum Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of FULC?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.